Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 6;2014(2):CD010314.
doi: 10.1002/14651858.CD010314.pub2.

Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews

Christopher J Cates  1 , L Susan Wieland, Marta Oleszczuk, Kayleigh M Kew
Affiliations

Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews

Christopher J Cates et al. Cochrane Database Syst Rev. .

Abstract

Background: For adults with asthma that is poorly controlled on inhaled corticosteroids (ICS), guidelines suggest adding a long-acting beta2-agonist (LABA). The LABA can be taken together with ICS in a single (combination) inhaler. Improved symptom control can be assessed in the individual; however, the long-term risk of hospital admission or death requires evidence from randomised controlled trials. Clinical trials record these safety outcomes as non-fatal and fatal serious adverse events (SAEs), respectively.

Objectives: To assess the risk of serious adverse events in adults with asthma treated with regular maintenance formoterol or salmeterol compared with placebo, or when randomly assigned in combination with regular ICS, compared with the same dose of ICS.

Methods: We included Cochrane reviews on the safety of regular formoterol and salmeterol from a June 2013 search of the Cochrane Database of Systematic Reviews. We carried out a search for additional trials in September 2013 and incorporated the new data. All reviews were independently assessed for inclusion and for quality (using the AMSTAR tool). We extracted from each review data from trials recruiting adults (participants older than 12 or 18 years of age).We combined the results from reviews on formoterol and salmeterol to assess the safety of twice-daily regular LABA as a class effect, both as monotherapy versus placebo and as combination therapy versus the same dose of ICS.We did not combine the results of direct and indirect comparisons of formoterol and salmeterol, or carry out a network meta-analysis, because of concerns over transitivity assumptions that posed a threat to the validity of indirect comparisons.

Main results: We identified six high-quality, up-to-date Cochrane reviews. Of these, four reviews (89 trials with 61,366 adults) related to the safety of regular formoterol or salmeterol as monotherapy or combination therapy. Two reviews assessed safety from trials in which adults were randomly assigned to formoterol versus salmeterol. These included three trials with 1116 participants given monotherapy (all prescribed background ICS) and 10 trials with 8498 adults receiving combination therapy. An additional search for trials in September 2013 identified five new included studies contributing data from 693 adults with asthma treated with combination formoterol/fluticasone in comparison with the same dose of inhaled fluticasone, as well as from 447 adults for whom formoterol monotherapy was compared with placebo.No trials reported separate results in adolescents. Overall, risks of bias for the primary outcomes were assessed as low. Death of any causeNone of the reviews found a significant increase in death of any cause from direct comparisons; however, none of the reviews could exclude the possibility of a two-fold increase in mortality on regular formoterol or salmeterol (as monotherapy vs placebo or as combination therapy versus ICS) in adults with asthma. Pooled mortality results from direct comparisons were as follows: formoterol monotherapy (odds ratio (OR) 4.49, 95% confidence interval (CI) 0.24 to 84.80, 13 trials, N = 4824), salmeterol monotherapy (OR 1.33, 95% CI 0.85 to 2.08, 10 trials, N = 29,128), formoterol combination (OR 3.56, 95% CI 0.79 to 16.03, 25 trials, N = 11,271) and salmeterol combination (OR 0.90, 95% CI 0.31 to 2.6, 35 trials, N = 13,447). In each case, we did not detect heterogeneity, and the quality of evidence was rated as moderate. Absolute differences in mortality were very small, translating into an increase of 7 per 10,000 over 26 weeks on any monotherapy (95% CI 2 less to 23 more) and 3 per 10,000 over 32 weeks on any combination therapy (95% CI 3 less to 17 more).Very few deaths were reported in the combination therapy trials, and combination therapy trial designs were different from those of monotherapy trials. Therefore we could not use indirect evidence to assess whether regular combination therapy was safer than regular monotherapy.Only one death occurred in the monotherapy trials comparing formoterol versus salmeterol, so evidence was insufficient to compare mortality. Non-fatal serious adverse events of any causeDirect evidence showed that non-fatal serious adverse events were increased in adults receiving salmeterol monotherapy (OR 1.14, 95% 1.01 to 1.28, I(2) = 0%,13 trials, N = 30,196) but were not significantly increased in any of the other reviews: formoterol monotherapy (OR 1.26, 95% CI 0.78 to 2.04, I(2) = 15%, 17 trials, N = 5758), formoterol combination (OR 0.99, 95% CI 0.77 to 1.27, I(2) = 0%, 25 trials, N = 11,271) and salmeterol combination (OR 1.15, 95% CI 0.91 to 1.44, I(2) = 0%, 35 trials, N = 13,447). This represents an absolute increase on any monotherapy of 43 per 10,000 over 26 weeks (95% CI 6 more to 85 more) and 16 per 10,000 over 32 weeks (95% CI 22 less to 60 more) on any combination therapy.Direct comparisons of formoterol and salmeterol detected no significant differences between risks of all non-fatal events in adults (as monotherapy or as combination therapy).

Authors' conclusions: Available evidence from the reviews of randomised trials cannot definitively rule out an increased risk of fatal serious adverse events when regular formoterol or salmeterol was added to an inhaled corticosteroid (as background or as randomly assigned treatment) in adults or adolescents with asthma.An increase in non-fatal serious adverse events of any cause was found with salmeterol monotherapy, and the same increase cannot be ruled out when formoterol or salmeterol was used in combination with an inhaled corticosteroid, although possible increases are small in absolute terms.However, if the addition of formoterol or salmeterol to an inhaled corticosteroid is found to improve symptomatic control, it is safer to give formoterol or salmeterol in the form of a combination inhaler (as recommended by the US Food and Drug Administration (FDA)). This prevents the substitution of LABA for an inhaled corticosteroid if symptom control is improved on LABA.The results of three large ongoing trials in adults and adolescents are awaited; these will provide more information on the safety of combination therapy under less supervised conditions and will report separate results for the adolescents included.

PubMed Disclaimer

Conflict of interest statement

Chris Cates authored the included systematic reviews on adverse events of long‐acting beta2‐agonists in adults and children and therefore was not involved in the assessment of quality of the reviews.

Figures

1
1
Network of comparisons of serious adverse events from reviews of regular formoterol and salmeterol. Figure 1A shows the numbers of trials and adults on monotherapy versus placebo. Figure 1B shows the numbers of trials and adults on combination therapy versus the same dose of ICS. Adults randomly assigned to other arms in the included trials have not been counted.
2
2
Review selection flow diagram.
3
3
Formoterol or salmeterol monotherapy versus placebo (with variable background use of ICS).
4
4
Formoterol monotherapy versus salmeterol monotherapy.
5
5
Formoterol or salmeterol combination therapy versus the same dose of ICS.
6
6
Formoterol combination therapy versus salmeterol combination therapy.
See this image and copyright information in PMC

Update of

References

References to included reviews

Cates 2008
    1. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006363.pub2] - DOI - PMC - PubMed
Cates 2010
    1. Cates CJ, Lasserson TJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD007694.pub2] - DOI - PMC - PubMed
Cates 2012a
    1. Cates CJ, Cates MJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD006923.pub3] - DOI - PMC - PubMed
Cates 2012b
    1. Cates CJ, Lasserson TJ. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD007695.pub3] - DOI - PMC - PubMed
Cates 2013a
    1. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD006922.pub3] - DOI - PubMed
Cates 2013b
    1. Cates CJ, Jaeschke R, Schmidt S, Ferrer M. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD006924.pub3] - DOI - PubMed

Additional references

Altman 2003
    1. Altman DG, Bland JM. Statistics notes: interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219. - PMC - PubMed
Anderson 2008
    1. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008;372(9643):1107‐19. [1474‐547X: (Electronic)] - PubMed
Boushey 1980
    1. Boushey HA, Holtzman MJ, Sheller JR, Nadel JA. Bronchial hyperreactivity. American Review of Respiratory Disease 1980;121(2):389‐413. [(Print)] - PubMed
Bradburn 2007
    1. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events. Statistics in Medicine 2007;26(1):53‐77. [0277‐6715: (Print)] - PubMed
Bucher 1997
    1. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta‐analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683‐91. - PubMed
Castle 1993
    1. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306(6884):1034‐7. - PMC - PubMed
Cates 2011
    1. Cates CJ. Assessing the risks of serious adverse events from regular long‐acting beta‐agonists for adults and children with asthma. MD Thesis, University of Cambridge, 2011.
Cates 2012c
    1. Cates CJ, Oleszczuk M, Stovold E, Wieland LS. Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD010005] - DOI - PMC - PubMed
Chan 2004
    1. Chan A‐W, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291(20):2457‐65. - PubMed
Chan 2004a
    1. Chan A‐W, Krleza‐Jeric K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. Canadian Medical Association Journal 2004;171(7):735‐40. - PMC - PubMed
Chowdhury 2011
    1. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. The New England Journal of Medicine 2011;364(26):2473‐5. - PubMed
Cipriani 2013
    1. Cipriani A, Higgins JPT, Geddes JR, Salanti G. Conceptual and technical challenges in network meta‐analysis. Annals of Internal Medicine 2013;159:130‐7. - PubMed
Cockcroft 2006
    1. Cockcroft D. Airway hyper‐responsiveness as a determinant of the early asthmatic response to inhaled allergen. Journal of Asthma 2006;43(3):175‐8. - PubMed
Corren 2013
    1. Corren J, Mansfield LE, Pertseva T, Blahzko V, Kaiser K. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate‐to‐severe asthma. Respiratory Medicine 2013;107:180‐95. - PubMed
GINA 2012
    1. GINA. Global strategy for asthma management and prevention. http://www.ginasthma.org/local/uploads/files/GINA_Report_March13.pdf (accessed 9 February 2013).
Ioannidis 2001
    1. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285(4):437‐43. [0098‐7484: (Print)] - PubMed
Ioannidis 2004
    1. Ioannidis JPA, Evans SJW, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781‐8. - PubMed
Lougheed 2010
    1. Lougheed MD, Lemiere C, Dell SD, Ducharme FM, Fitzgerald JM, Leigh R, et al. Canadian Thoracic Society Asthma Committee commentary on long‐acting beta‐2 agonist use for asthma in Canada. Canadian Respiratory Journal 2010;17(2):57‐8. - PMC - PubMed
Matsunaga 2013
    1. Matsunaga K, Kawabata H, Hirano T, Sugiura H, Minakata Y, Ichinose M. Difference in time‐course of improvement in asthma control measures between budesonide and budesonide/formoterol. Pulmonary Pharmacology & Therapeutics 2013;26:189‐94. - PubMed
McMahon 2011
    1. McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA–approved long‐acting β2‐adrenergic receptor agonists. Pediatrics 2011;128(5):e1147‐54. - PubMed
Nathan 2012
    1. Nathan R A, D'Urzo A, Blazhko V, Kaiser K. Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild‐to‐moderate asthma: a randomised controlled trial. BMC Pulmonary Medicine 2012;12:67. - PMC - PubMed
NCT01444430
    1. AstraZeneca. A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents. http://clinicaltrials.gov/show/NCT01444430 (accessed June 2012).
NCT01462344
    1. GlaxoSmithKline. 6‐Month Safety and Benefit Study of ADVAIR in Children 4‐11 Years Old (VESTRI). http://clinicaltrials.gov/show/NCT01462344 (accessed 29 June 2012).
NCT01471340
    1. Merck. A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3) (SPIRO). http://clinicaltrials.gov/ct2/show/NCT01471340 (accessed June 2012).
NCT01475721
    1. GlaxoSmithKline. SAS115359: A 6‐Month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. (AUSTRI). http://clinicaltrials.gov/show/NCT01475721 (accessed June 2012).
Pearlman 2013
    1. Pearlman DS, LaForce CF, Kaiser K. Fluticasone/Formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. Clinical Therapeutics 2013;35:950‐66. - PubMed
Phillips 1990
    1. Phillips GD, Finnerty JP, Holgate ST. Comparative protective effect of the inhaled beta‐2‐agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5'‐monophosphate in asthma. Journal of Allergy and Clinical Immunology 1990;85(4):755‐62. - PubMed
RevMan 5.2 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) 5.2. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Salpeter 2006
    1. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta‐analysis: effect of long‐acting beta‐agonists on severe asthma exacerbations and asthma‐related deaths. Annals of Internal Medicine 2006;144(12):904‐12. - PubMed
Sears 2013
    1. Sears MR, Radner F. Safety of formoterol in asthma clinical trials: an update. European Respiratory Journal Epub 30 May 2013. [DOI: 10.1183/09031936.00004713] - DOI - PubMed
Shea 2007
    1. Shea B, Grimshaw J, Wells G, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007;7:10. [DOI: 10.1186/1471-2288-7-10] - DOI - PMC - PubMed
SIGN/BTS 2012
    1. Scottish Intercollegiate Guidelines Network/British Thoracic Society. British guideline on the management of asthma: a national clinical guideline 2008 (revised January 2012). http://www.sign.ac.uk/guidelines/fulltext/101/. Edinburgh: Scottish Intercollegiate Guidelines Network, (accessed 9 February 2013).
SMART 2006
    1. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15‐26. - PubMed
Stirbulov 2012
    1. Stirbulov R, Fritscher CC, Pizzichini E, Pizzichini MMM. Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial. Jornal Brasileiro de Pneumologia 2012;38:431‐7. - PubMed
Tattersfield 2006
    1. Tattersfield AE. Current issues with beta2‐adrenoceptor agonists: historical background. Clinical Reviews in Allergy and Immunology 2006;31(2‐3):107‐18. - PubMed
Van Noord 1996
    1. Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. European Respiratory Journal 1996;9(8):1684‐8. - PubMed
Visual Rx 2012
    1. Cates CJ. Visual Rx 3.0. www.nntonline.net/visualrx/ (September 2008).
Weinberger 2006
    1. Weinberger M, Abu‐Hasan M. Life threatening asthma during treatment with salmeterol. New England Journal of Medicine 2006;355:852‐3. - PubMed
Whittington 2004
    1. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363(9418):1341‐5. - PubMed

Publication types

MeSH terms